KRON

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that target the transcriptional machinery of cancer cells. By utilizing its proprietary Product Engine, the company maps transcriptional regulatory networks to identify vulnerabilities in targets that have historically been considered undruggable, such as transcription factors. The lead program, KB-0742, is a selective, orally bioavailable inhibitor of CDK9 currently in Phase 1/2 clinical trials for MYC-amplified solid tumors. Kronos Bio's approach combines high-throughput screening with advanced computational biology to create a pipeline of small molecule inhibitors for various oncogenic drivers. Headquartered in San Mateo, California, the company aims to address significant unmet needs in oncology by leveraging its deep expertise in transcriptional biology.